Ibrutinib resistance in chronic lymphocytic leukemia.
نویسندگان
چکیده
n engl j med 370;24 nejm.org june 12, 2014 2352 portant questions both about the nature of the evidence and about its sufficiency, a topic that has been the subject of inquiry and discussion in the patient-safety community for well over a decade.1 As noted in the editorial, replications have confirmed substantial effects regarding the use of a surgical checklist, but rigorous randomized trials have not been carried out and are unlikely to be. In contrast to the relatively simple act of providing a new drug or procedure, implementing the surgical checklist calls for performance of a diverse array of 20 or more actions, which can, and should, vary from one institution to another. An even more important barrier to performing a randomized trial is that implementation of the checklist almost always requires major culture change. Although culture can (and should) be measured, because of its unique nature in a given operating suite (even among individual rooms), the more relevant comparison after implementation of a checklist is with the prior condition, a before-versus-after study, not with other organizations with very different cultures. The key culture change facilitated by the surgical checklist is the development of highly functioning teams, the value of which is well supported by evidence from many venues in and out of health care. Weiser and Krummel reemphasize the key learnings from all checklist replication studies: success requires great effort directed toward the implementation process and strong leadership, a point also made by Haynes et al., who in addition note that the 9% reduction in mortality that Urbach et al. report could be a significant trend if mortality was followed for a longer time period. Robblee notes a potential benefit from implementing the surgical checklist that has been underappreciated in the literature: the identification of near misses, which are defined as errors or malfunctions that might well have caused harm if they had not been intercepted. If these events are analyzed, the underlying process failures (socalled latent failures) can often be identified and the process redesigned to prevent the errors from recurring. Indeed, if and when performance of the surgical checklist is fully institutionalized as an integral part of a culture of everyday teamwork in the operating room, it may turn out that one of its major benefits will be identifying opportunities for process improvement. Lucian L. Leape, M.D.
منابع مشابه
Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Despite ibrutinib activity in multiple B-cell malignancies, cases of primary and secondary resistance have emerged. The overall reported frequency of resistance is low. Resistance has been found to be caused by a mutation in the BTK binding site of ibrutinib or gain-of-function mutations in PLCG2, which lead to autonomous BCR activity. Improved understanding of mechanisms of primary and seconda...
متن کاملSuccessful treatment with ibrutinib of intractable thrombocytopenia associated with recurrent chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is characterized by lymphocytosis with mild progression, although some CLL patients develop fatal cytopenia. This report describes a 69-year-old Japanese man with CD8 CD19 CLL presenting with severe thrombocytopenia. Because he showed extreme resistance to various conventional regimens, we administered a novel agent, ibrutinib. Besides a striking reduction in ...
متن کاملBruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLCγ2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibruti...
متن کاملSelinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses are infrequent, and acquired resistance to Bruton agammaglobulinemia tyrosine kinase (BTK) inhibition is being observed in an increasing number of patients. Combination regimens that increase frequency of complete remissions, accelerate time to remission, and overcome single agent resistance ...
متن کاملEvolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initially responds to the BTKi and then develops resistance. Estimating the frequency, timing, and individua...
متن کاملIbrutinib-Associated Nail Plate Abnormalities: Case Reports and Review
Chronic lymphocytic leukemia is a lymphoproliferative disorder characterized by a gradual accumulation of neoplastic B-lymphocytes. Ibrutinib is a novel therapy for chronic lymphocytic leukemia. Ibrutinib therapy has been associated with nail plate abnormalities. Other common cutaneous adverse events caused by ibrutinib appear to be bruising, hair changes, pruritus, and rashes. We describe the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The New England journal of medicine
دوره 370 24 شماره
صفحات -
تاریخ انتشار 2014